Here are Friday's biggest analyst calls: Nvidia, SpaceX, Tesla, Amazon, Marvell, Affirm & more

Wall Street’s biggest calls skew positive: Evercore lifted Amazon to $355 (from $315) after survey evidence that “agentic AI” is additive for retail, while CLSA upgraded Baozun to $3.80 (from $3.20) implying 26% upside on improving profitability. Bank of America raised Affirm’s target to $104 (from $93) post-earnings and reiterated Marvell as accelerating growth toward mid-50s YoY. In coverage initiations, William Blair set TeraWulf fair value at $31 implying ~92% upside, and Argus upgraded Moderna on positive Phase 3 personalized cancer vaccine results with a plan to engage regulators.

Analysis

The common thread is not “good earnings” or “good stock picks”; it is the market rewarding businesses that can convert optionality into scale without heavy balance-sheet intensity. That favors AMZN and NVDA on a 6-18 month horizon because their upside comes from distribution and ecosystem lock-in, while it caps the duration of moves in smaller-cap names where re-rating depends on continued access to cheap capital or perfect execution.

Second-order winners are the suppliers and adjacent enablers that monetize adoption, not just the headline beneficiaries. If Amazon’s retail tooling improves conversion, the pressure lands on lower-intent merchants and off-price chains first; if Tesla keeps pricing robotaxi access aggressively, the near-term benefit is user acquisition, but the strategic cost is slower monetization versus peers, which keeps the stock a “show-me” story rather than a clean margin inflection.

The contrarian risk is that several of these calls are consensus reinforcement rather than fresh information, so follow-through may be limited unless the next data point confirms it. For MRNA, the gap between promising biology and regulatory acceptability remains the key binary; for WULF, TMCR, and OSG, the stock reaction will likely be driven more by financing conditions and liquidity than by target prices. Falsifiers: any slowdown in Amazon conversion metrics, NVDA cloud-order digestion, or a regulatory pushback on MRNA would quickly unwind the current optimism.

Key Decisions for Investors

• Long AMZN vs short TGT or XRT over the next 4-8 weeks: express the view that improved AI-driven conversion and share gains will outperform broad discretionary retail; stop if holiday traffic data or conversion evidence disappoints.
• Buy NVDA on pullbacks, preferably via call spreads for 1-3 months: the re-rating case is still intact, but upside is incremental rather than explosive; risk/reward weakens if hyperscaler capex commentary decelerates.
• Wait for regulatory confirmation before adding MRNA; if the company gets an explicit path to filing/engagement acceptance, use a small starter long or call spread, but treat this as a binary event with high gap risk.
• Avoid chasing WULF, TMCR, and OSG after initial upgrades; these are higher-beta, financing-sensitive names where upside can disappear if rates, power costs, or capital markets tighten. If trading them, keep it tactical and sized small.
• Use TSLA as a relative-value short against better monetization stories only if pricing competition persists into the next update; otherwise, the current data supports patience rather than an aggressive short.